


MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Adams Memorial Hospital</p> <p>2. 1100 Mercer Ave. Decatur, IN 46733</p>	<p>In accordance with letter dated January 12, 2018.</p> <p>3. License number: 13-26133-01 is amended in its entirety to read as follows:</p>	<p>4. Expiration Date: August 31, 2025</p> <p>5. Docket No.: 030-31518 Reference No.:</p>
--	---	---



6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 1 curie total	C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.

CONDITIONS

- 10. Licensed material may be used or stored at the licensee's facilities located at 1100 Mercer Ave., Decatur, Indiana, 46733.
- 11. The Radiation Safety Officer (RSO) for this license is John Pasalich, M.D.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
13-26133-01

Docket or Reference Number
030-31518

Amendment No. 7

12. Licensed material shall only be used by, or under the supervision of:

A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.

B. The following individuals are authorized users for the material and medical uses as indicated:

<u>Authorized User(M.D.,D.O.,etc.)</u>	<u>Material and Use</u>
James A. Arata, M.D.	10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300
John L. Bormann, M.D.	10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300
Daniel Branam, M.D.	10 CFR 35.100, 10 CFR 35.200
Joseph R. Decamp, M.D.	10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)
Brett A. Hagedorn, M.D.	10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300
Eric V. Heatwole, M.D.	10 CFR 35.100, 10 CFR 35.200
David B. Janizek, M.D.	10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300
Shawn Johnson, M.D.	10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300
Christopher M. Kowalski, M.D.	10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries for imaging and localization studies)
Michael E. Parker, M.D.	10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300
John Pasalich, M.D.	10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300
Dakshesh S. Patel, M.D.	10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries for imaging and localization studies)
Randall J. Phillips, M.D.	10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300
John Rock, M.D.	10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries for imaging and localization studies)
Richard W. Sibley, M.D.	10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300
Richard P. Stephens, Jr., M.D.	10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
13-26133-01

Docket or Reference Number
030-31518

Amendment No. 7

Authorized User(M.D.,D.O.,etc.)

Andre B. Stovall, M.D.

Pamela Lee Strange, M.D.

Marc Thomas, M.D.

Frederick N. Vandeman, M.D.

James C. Wehrenberg, M.D.

Material and Use


10 CFR 35.100,10 CFR 35.200,10 CFR 35.300

10 CFR 35.100,10 CFR 35.200,10 CFR 35.300

10 CFR 35.100,10 CFR 35.200,10 CFR 35.300

10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)


10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries for imaging and localization studies)



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
13-26133-01Docket or Reference Number
030-31518

Amendment No. 7

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated February 12, 2015 (ML15051A490)
- B. Letter dated July 1, 2015 (ML15230A541)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: MAY 31 2018By: Cassandra F. Frazier
Region 3